In the Matter of GlaxoSmithKline, PLC (Augmentin)
States alleged that GlaxoSmithKline fraudulently obtained patent protection for Augmentin and then delayed generic entry through sham patent litigation. Through this conduct, GlaxoSmithKline unlawfully maintained its monopoly over Augmentin. A $3.5 million multistate settlement for state proprietary claims was entered into by the participating states and GlaxoSmithKline.
In Re Relafen Antitrust Litigation
States sued manufacturer of antidepressant Relafen, alleging patent misuse and sham litigation designed to prevent generic entry. Parties settled the state proprietary claims for $10 million.
Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)
States sued manufacturer of antitdepressant Paxil, alleging patent misuse and sham litigation designed to prevent generic entry. Parties settled for $14 million.
Nixon et al., v. Cargill, Inc., No. 4:97-cv-0687 (E.D.Mo.)April 1997)
Northern Mississippi River and Ohio River States sought to minimize the impact of the merger of Cargill and Akzo by divestiture of bulk deicing salt supply agreement.
Iowa v. Larrry Bentler, et al.,
State settled with three gasoline retailers accused of fixing prices in Mt. Pleasant, Iowa.
Missouri, et al vs. Arch Coal, Inc and New Vulcan Coal Holdings, LLC and Triton Coal Company, LLC, US District Court, District of Columbia – No. 1:04CV00535
Merger review of two of the most dominant coal producers in the Permian Basin.
U.S. et al. v. EchoStar Communications, Corp., et al. No. 1:02CV02138 (D.D.C.)
Federal and State action to enjoin merger of two direct broadcast satellite (DBS) companies. The merging parties abandoned their merger agreement
Iowa ex rel. Miller v. Wells Dairy, Inc., No. CE00038663 IA Dist. Ct. Polk Cty.1999)
Bid-rigging scheme for school milk contracts
Connecticut v. Mylan Laboratories, Inc. (In re Lorazepam & Clorazepate Antitrust Litigation), MDL No. 1290 (D.D.C. June 15, 2000) 205 F.R.D. 369 (D.D.C. 2002); No. 98 CV 3115 (D.D.C. 2000) – complaint
Plaintiff States alleged that Mylan Laboratories, Inc.(Mylan) and other drug companies entered into illegal agreements to monopolize the market for certain generic anti-anxiety drugs.
New York v. Microsoft Corp., 97 F. Supp. 2d 59 (D.D.C. 2000)
U.S. Department of Justice and the Plaintiff States alleged that the Defendant, Microsoft Corporation violated State and Federal law by maintaining a monopoly in the market for Intel-compatible personal computer operating systems and by illegally tying its Windows operating system to its Internet Explorer browser.
